HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

JSM6427

integrin alpha5beta1 antagonist

Networked: 6 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Propionates: 988
      - JSM6427: 6
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Propionates: 988
      - JSM6427: 6
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - JSM6427: 6
  - Pyridines: 88
    - JSM6427: 6

Experts

1.	Stragies, Roland: 5 articles (02/2010 - 06/2006)
2.	Zahn, Grit: 5 articles (02/2010 - 06/2006)
3.	Vossmeyer, Dörte: 4 articles (02/2010 - 09/2007)
4.	Adamis, Anthony P: 2 articles (02/2010 - 10/2009)
5.	Knolle, Jochen: 2 articles (02/2010 - 10/2009)
6.	Löffler, Karin U: 2 articles (02/2010 - 10/2009)
7.	Barkan, Dalit: 1 article (12/2011)
8.	Chambers, Ann F: 1 article (12/2011)
9.	Chapin, Ethan A: 1 article (02/2010)
10.	Daniel, Paul E: 1 article (02/2010)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2008 - "21 days after glioma cell injection into an experimental mouse model, the tumor volume was significantly smaller after treating animals for 14 days with JSM6427 as compared to controls. " 12/01/2008 - "Slices injected with glioma cells were treated with the integrin inhibitor JSM6427 and showed a significant reduction in tumor size as compared to control. " 12/01/2008 - "We show, that an inhibitor of alpha5 beta1 integrin (alpha5beta1), JSM6427, attenuated glioma growth and decreased the density of microglia at the tumor border. " 12/01/2011 - "We also consider possible therapeutic approaches, such as small molecules or antibodies (ATN-161, volociximab, and JSM6427), directed against β1-integrin signaling to target dormant cancer cells and to prevent metastatic recurrence."
2.	Glioma (Gliomas) 12/01/2008 - "21 days after glioma cell injection into an experimental mouse model, the tumor volume was significantly smaller after treating animals for 14 days with JSM6427 as compared to controls. " 12/01/2008 - "Slices injected with glioma cells were treated with the integrin inhibitor JSM6427 and showed a significant reduction in tumor size as compared to control. " 12/01/2008 - "We show, that an inhibitor of alpha5 beta1 integrin (alpha5beta1), JSM6427, attenuated glioma growth and decreased the density of microglia at the tumor border. " 12/01/2008 - "Depleting microglial cells from the slice culture by treatment with clodronate liposomes abrogated the effect of JSM6427 on glioma invasion indicating that the presence of microglia is required. "
3.	Choroidal Neovascularization 10/01/2009 - "To evaluate the pharmacologic activity and tolerability of JSM6427, a potent and first selective small-molecule inhibitor of integrin alpha5beta1, in monkey and rabbit models of choroidal neovascularization (CNV). " 10/01/2009 - "Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization." 06/01/2006 - "Implantation of an osmotic pump delivering 1.5 or 10 microg/h ( approximately 1.8 or 12 mg/kg/day) of 3-(2-{1-alkyl-5-[(pyridin-2-ylamino)-methyl]-pyrrolidin-3-yloxy}-acetylamino)-2-(alkylamino)-propionic acid (JSM6427), a selective alpha(5)beta(1) antagonist, caused significant suppression of choroidal neovascularization; the area of neovascularization was reduced by 33 to 40%. "
4.	Proliferative Vitreoretinopathy 02/01/2010 - "To explore the role of integrin alpha5beta1 in proliferative vitreoretinopathy (PVR) pathogenesis by evaluating the expression alpha5beta1 on ARPE-19 cells and patient proliferative membranes, quantifying the inhibitory effects of JSM6427 (a small molecule alpha5beta1 inhibitor) on ARPE-19 cell adhesion and migration, and assessing the therapeutic potential of JSM6427 in a rabbit retinal detachment model. " 02/01/2010 - "Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment."
5.	Rupture 06/01/2006 - "When an osmotic pump delivering 10 microg/h of JSM6427 was implanted 7 days after rupture of Bruch's membrane, there was terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining in vascular cells within the neovascularization and significant regression of the neovascularization over the next week. "

Related Drugs and Biologics

1.	Integrins
2.	Integrin alpha5beta1
3.	Integrin beta1
4.	Retinaldehyde (Retinal)
5.	Liposomes (Liposome)
6.	DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)
7.	Clodronic Acid (Clodronate)
8.	Bromodeoxyuridine (BrdU)
9.	Antibodies
10.	volociximab

Related Therapies and Procedures

1.	Intravitreal Injections